Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | RXRA | P19793 | 1/20 | 0.70 |
| ▸ | RXRB | P28702 | 1/20 | 0.70 |
| ▸ | MRGPRX4 | Q96LA9 | 11/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | XBP1 | P17861 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | MITF | O75030 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | RELA | Q04206 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243754 | 0.88 | MRGPRX4 (0.73) | HPGDRXRARXRBMRGPRX4NPC1 | |
| SCHEMBL20830739 | 0.87 | HPGD (0.57) | HPGDRXRARXRBMRGPRX4NPC1 | |
| Hydrochloric Acid SCHEMBL9647665 | 0.86 | MRGPRX4 (0.71) | HPGDRXRARXRBMRGPRX4NPC1 | |
| SCHEMBL3758648 | 0.86 | HPGD (0.64) | HPGDRXRARXRBMRGPRX4NPC1 | |
| SCHEMBL559537 | 0.85 | NOTUM (0.58) | HPGDRXRARXRBMRGPRX4NPC1 | |
| SCHEMBL1600077 | 0.85 | MRGPRX4 (0.62) | HPGDRXRARXRBMRGPRX4NPC1 | |
| SCHEMBL29556736 | 0.85 | MRGPRX4 (0.62) | HPGDRXRARXRBMRGPRX4NPC1 | |
| Hydrochloric Acid SCHEMBL10857748 | 0.84 | MRGPRX4 (0.61) | HPGDRXRARXRBMRGPRX4NPC1 | |
| SCHEMBL2634130 | 0.83 | NR4A2 (0.63) | HPGDRXRARXRBMRGPRX4NPC1 | |
| SCHEMBL3960943 | 0.83 | NR4A2 (0.58) | HPGDRXRARXRBMRGPRX4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS (US) | 2024-02-29 | — | — | US | disclosed |
| US-20220396547-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIV KANSAS (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220396547-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIV KANSAS (US) | 2022-12-15 | — | — | US | disclosed |
| US-10865181-B2 | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) | UNIVERSITY OF KANSAS (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865181-B2 | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) | UNIVERSITY OF KANSAS (US) | 2020-12-15 | — | — | US | disclosed |
| US-20180282264-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS | 2018-10-04 | — | — | US | disclosed |
| EP-3215152-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | The University of Kansas (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073633-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS (US) | 2016-05-12 | — | — | WO | disclosed |
| US-8946438-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8735579-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735579-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| EP-2331506-B1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-03 | — | — | EP | disclosed |
| EP-2331506-B1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120108572-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108572-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108572-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| EP-2331506-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010026095-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026095-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | HPGD 651/4885RXRA 3977/4885RXRB 3846/4885 |
| US-20220396547-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | HPGD 651/4885RXRA 3977/4885RXRB 3846/4885 |
| US-20180282264-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | HPGD 651/4885RXRA 3977/4885RXRB 3846/4885 |
| US-20120108572-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | HRH2, HRH1, HRH4 | HPGD 1201/4885RXRA 919/4885RXRB 1372/4885 |
| US-10865181-B2 | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) | MTCH2, TIMM50, TIMM10 | HPGD 651/4885RXRA 3977/4885RXRB 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.